FR17C1063I2 - Nouvelle utilisation de derives de staurosporine - Google Patents

Nouvelle utilisation de derives de staurosporine

Info

Publication number
FR17C1063I2
FR17C1063I2 FR17C1063C FR17C1063C FR17C1063I2 FR 17C1063 I2 FR17C1063 I2 FR 17C1063I2 FR 17C1063 C FR17C1063 C FR 17C1063C FR 17C1063 C FR17C1063 C FR 17C1063C FR 17C1063 I2 FR17C1063 I2 FR 17C1063I2
Authority
FR
France
Prior art keywords
warm
new use
treatment
derivatives
staurosporin derivatives
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
FR17C1063C
Other languages
English (en)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis Pharma GmbH
Novartis AG
Original Assignee
Novartis Pharma GmbH
Novartis AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=33539193&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=FR17C1063(I2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Pharma GmbH, Novartis AG filed Critical Novartis Pharma GmbH
Publication of FR17C1063I1 publication Critical patent/FR17C1063I1/fr
Application granted granted Critical
Publication of FR17C1063I2 publication Critical patent/FR17C1063I2/fr
Active legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/16—Peri-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Obesity (AREA)
  • Ophthalmology & Optometry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Child & Adolescent Psychology (AREA)
  • Otolaryngology (AREA)
  • Communicable Diseases (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
FR17C1063C 2003-06-18 2017-12-28 Nouvelle utilisation de derives de staurosporine Active FR17C1063I2 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US47957503P 2003-06-18 2003-06-18
EP04740016A EP1638574B1 (fr) 2003-06-18 2004-06-17 Nouvelle utilisation de derives de staurosporine
PCT/EP2004/006562 WO2004112794A2 (fr) 2003-06-18 2004-06-17 Nouvelle utilisation de derives de staurosporine

Publications (2)

Publication Number Publication Date
FR17C1063I1 FR17C1063I1 (fr) 2018-02-16
FR17C1063I2 true FR17C1063I2 (fr) 2019-05-03

Family

ID=33539193

Family Applications (1)

Application Number Title Priority Date Filing Date
FR17C1063C Active FR17C1063I2 (fr) 2003-06-18 2017-12-28 Nouvelle utilisation de derives de staurosporine

Country Status (24)

Country Link
US (2) US8575146B2 (fr)
EP (1) EP1638574B1 (fr)
JP (2) JP5057780B2 (fr)
CN (2) CN101164539A (fr)
AT (1) ATE464052T1 (fr)
AU (1) AU2004248909B2 (fr)
BE (1) BE2017C067I2 (fr)
BR (1) BRPI0411563B8 (fr)
CA (2) CA2785950A1 (fr)
CY (2) CY1110179T1 (fr)
DE (1) DE602004026578D1 (fr)
DK (1) DK1638574T3 (fr)
ES (1) ES2344700T3 (fr)
FR (1) FR17C1063I2 (fr)
HK (1) HK1095519A1 (fr)
HU (1) HUS000503I2 (fr)
LU (1) LUC00055I9 (fr)
MX (1) MXPA05013722A (fr)
NL (1) NL300917I2 (fr)
PL (1) PL1638574T3 (fr)
PT (1) PT1638574E (fr)
SI (1) SI1638574T1 (fr)
TW (1) TWI324604B (fr)
WO (1) WO2004112794A2 (fr)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI324604B (en) * 2003-06-18 2010-05-11 Novartis Ag New use of staurosporine derivatives
US20060014165A1 (en) * 2003-07-14 2006-01-19 Decode Genetics Ehf. Methods of diagnosis and treatment for asthma and other respiratory diseases based on haplotype association
CN1882344A (zh) 2003-11-18 2006-12-20 诺瓦提斯公司 Kit突变形式的抑制剂
WO2005115385A1 (fr) * 2004-05-24 2005-12-08 Ab Science Utilisation d'inhibiteurs de c-kit pour le traitement de l'acne
CN103251953A (zh) * 2004-07-19 2013-08-21 约翰·霍普金斯大学 供免疫抑制的flt3抑制剂
MX2007001155A (es) * 2004-07-29 2007-08-14 Creabilis Therapeutics Spa Uso de inhibidores de k-252a y de quinasa para la prevencion o el tratamiento de patologias asociadas con hmgb1.
GB0419159D0 (en) * 2004-08-27 2004-09-29 Novartis Ag Organic compounds
JP5129123B2 (ja) * 2005-05-02 2013-01-23 ノバルティス アーゲー 全身性肥満細胞症の処置のためのピリミジルアミノベンズアミド誘導体の使用
DE602006013826D1 (de) * 2005-07-20 2010-06-02 Peter Valent Zusammensetzungen zur behandlung von systemischer mastocytose
EP1951255A1 (fr) * 2005-11-14 2008-08-06 Universität Zürich Derives de la staurosporine utilisables dans le rhabdomyosarcome alveolaire
WO2009092442A1 (fr) * 2008-01-23 2009-07-30 Universidad De Barcelona Traitement de l'hypertension portale et d'états apparentés par une inhibition combinée des voies de signalisation de vegf et pdgf
US8802099B2 (en) * 2010-11-10 2014-08-12 National Jewish Health Methods to treat allergic conditions
CR20210287A (es) 2018-11-01 2022-02-15 Syros Pharmaceuticals Inc Inhibidores de cinasa 7 dependiente de ciclina (cdk7)
WO2020097261A1 (fr) * 2018-11-06 2020-05-14 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Nouvelles compositions et nouveaux procédés de traitement de globinopathies
US11839619B2 (en) * 2019-09-16 2023-12-12 The Regents Of The University Of California Methods for treatment of pediatric systemic mastocytosis

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4639455A (en) * 1984-10-02 1987-01-27 Key Pharmaceuticals, Inc. Means of aiding in the prevention of sudden infant death syndrome
JPH0826037B2 (ja) * 1987-01-22 1996-03-13 協和醗酵工業株式会社 生理活性物質ｋ−２５２の誘導体
US5093330A (en) * 1987-06-15 1992-03-03 Ciba-Geigy Corporation Staurosporine derivatives substituted at methylamino nitrogen
CA2046801C (fr) 1990-08-07 2002-02-26 Peter D. Davis Pyrroles substitues
DK0518468T3 (da) * 1991-05-09 2000-01-31 Neurim Pharma 1991 Melatoninholdige sammensætninger
AR004480A1 (es) 1995-04-06 1998-12-16 Amico Derin C D Compuestos de ascomicina que poseen actividad antiinflamatoria, pro cedimiento para prepararlos, uso de dichos compuestos para preparar agentesfarmaceuticos y composiciones farmaceuticas que los incluyen
NZ333441A (en) * 1996-06-25 1999-05-28 Cephalon Inc Use of k-252a derivatives for the treatment of peripheral or central nerve disorders, and cytokine overproduction
US6093740A (en) * 1997-04-30 2000-07-25 Eli Lilly And Company Therapeutic treatment for skin disorders
WO1999062537A1 (fr) * 1998-06-04 1999-12-09 The Rockefeller University Procedes et agents permettant la modulation de la reponse immunitaire et de l'inflammation par modulation des proteines membranaires des monocytes et des cellules dendritiques
GB9903547D0 (en) * 1999-02-16 1999-04-07 Novartis Ag Organic compounds
DE60112611T2 (de) * 2000-12-08 2006-06-14 Ortho Mcneil Pharm Inc Makroheterocyclische verbindungen als kinase inhibitoren
GB0108606D0 (en) * 2001-04-05 2001-05-23 Novartis Ag Organic compounds
EP1471907B1 (fr) * 2001-06-29 2008-07-16 AB Science Utilisation d'inhibiteurs de c-kit destines a traiter des maladies auto-immunes
US20030091974A1 (en) * 2001-06-29 2003-05-15 Alain Moussy Method for screening compounds capable of depleting mast cells
CN1582150B (zh) 2001-10-30 2011-09-07 诺瓦提斯公司 作为flt3受体酪氨酸激酶活性抑制剂的星形孢菌素衍生物
US6998391B2 (en) 2002-02-07 2006-02-14 Supergen.Inc. Method for treating diseases associated with abnormal kinase activity
EP1645286A1 (fr) * 2003-04-18 2006-04-12 Kyowa Hakko Kogyo Co., Ltd. Medicament pour la regeneration des nerfs
JPWO2004093910A1 (ja) * 2003-04-22 2006-07-13 アステラス製薬株式会社 ＰＰＡＲδアゴニストによる脳神経変性疾患治療剤
TWI324604B (en) * 2003-06-18 2010-05-11 Novartis Ag New use of staurosporine derivatives
CN1882344A (zh) 2003-11-18 2006-12-20 诺瓦提斯公司 Kit突变形式的抑制剂

Also Published As

Publication number Publication date
CA2527703A1 (fr) 2004-12-29
HUS000503I2 (hu) 2021-03-29
AU2004248909B2 (en) 2008-05-08
EP1638574A2 (fr) 2006-03-29
CY1110179T1 (el) 2015-01-14
AU2004248909A1 (en) 2004-12-29
CN100457111C (zh) 2009-02-04
DK1638574T3 (da) 2010-08-02
TWI324604B (en) 2010-05-11
EP1638574B1 (fr) 2010-04-14
CY2017048I2 (el) 2018-09-05
JP5057780B2 (ja) 2012-10-24
LUC00055I2 (fr) 2018-02-21
ES2344700T3 (es) 2010-09-03
PT1638574E (pt) 2010-07-14
BRPI0411563B1 (pt) 2019-09-24
JP2006527727A (ja) 2006-12-07
MXPA05013722A (es) 2006-03-08
JP2012144572A (ja) 2012-08-02
LUC00055I9 (fr) 2022-11-09
SI1638574T1 (sl) 2010-08-31
BE2017C067I2 (fr) 2023-08-09
WO2004112794A3 (fr) 2005-06-16
TW200512213A (en) 2005-04-01
BRPI0411563A (pt) 2006-08-01
DE602004026578D1 (de) 2010-05-27
CN101164539A (zh) 2008-04-23
CA2785950A1 (fr) 2004-12-29
FR17C1063I1 (fr) 2018-02-16
LUC00055I1 (fr) 2017-12-14
US20070299049A1 (en) 2007-12-27
US8575146B2 (en) 2013-11-05
WO2004112794A2 (fr) 2004-12-29
BRPI0411563B8 (pt) 2021-05-25
CA2527703C (fr) 2012-10-23
NL300917I2 (nl) 2018-01-09
ATE464052T1 (de) 2010-04-15
US20130289018A1 (en) 2013-10-31
HUS1700053I1 (hu) 2018-01-29
CN1805749A (zh) 2006-07-19
NL300917I1 (nl) 2017-12-12
PL1638574T3 (pl) 2010-09-30
HK1095519A1 (en) 2007-05-11
CY2017048I1 (el) 2018-09-05

Similar Documents

Publication Publication Date Title
FR17C1063I2 (fr) Nouvelle utilisation de derives de staurosporine
DK1611088T3 (da) Hydroxymater som terapeutiske midler
NO20061253L (no) Acetylenderivater som inhibitorer av histon deacetylase
ATE520668T1 (de) Sigmarezeptor-inhibitoren
EA200971053A1 (ru) Способы лечения кожных язв
SG170101A1 (en) 2-pyrazinone derivatives for the treatment of disease or condition in which inhibition of neutrophil elastase activity is beneficial.
ATE452129T1 (de) N-phenyl-2-pyrimidine-amine derivatives
ATE411022T1 (de) Pyridylpyrrol-derivate als wirksame kinase-hemmer
NO20060573L (no) 2-imino-4-(tio)okso-5-polysyklovinylazoliner for anvendelse som PI3 kinasehemmere
NO20084912L (no) Bisykliske derivater som CETP-inhibitorer
EA201390353A1 (ru) Производное пиразолохинолина
ATE529417T1 (de) 3',4',5-trimethoxyflavonderivate als die schleimsekretion stimulierendes mittel, entsprechendes verfahren und pharmazeutische zusammensetzung, die diese enthält
BR0313718A (pt) Composto, processo para a preparação do mesmo, composição farmacêutica, métodos para tratar um indivìduo humano ou animal sofrendo de uma condição que é mediada por cox-2 e para tratar um indivìduo humano ou animal sofrendo de um distúrbio inflamatório, e, uso de um composto
ATE547105T1 (de) Glucosamin und derivate davon als transglutaminase-inhibitoren zur verwendung in der behandlung von einer funktionsstörung des nervensystems
NO20051936L (no) Anvendelse av 4-pyridylmetyl-ftalazinderivater for fremstilling av et medikament for behandling av myelodysplastiske syndromer.
ATE365038T1 (de) ARZNEIMITTEL ZUR BEHANDLUNG DES ßSYSTEMIC INFLAMMATORY RESPONSE SYNDROMEß
TH401002069A (th) การใช้แบบใหม่ของอนุพันธ์สเทาโรสพอรีน
ATE412630T1 (de) C2-disubstituierte indan-1-ol-systeme und ihre verwendung als arzneimittel